Hepatitis
Conference Coverage
A bold national plan to eliminate HCV by 2050
“We don’t get to use the ‘eliminate’ word all that often with a disease that’s taking thousands or tens of thousands – or worldwide, hundreds of...
Conference Coverage
Bepirovirsen: Is a ‘functional cure’ for HBV on the horizon?
“Bepirovirsen is just one RNA-based HBV therapy now being pursued. Several other antisense RNAs as well as the more malleable small interfering...
Conference Coverage
World falls short on HBV, HCV elimination targets
“As countries progress toward eliminating hepatitis B and C, we really need to do more to expand political will and financing of national...
News from the FDA/CDC
FDA expands tenofovir alafenamide (Vemlidy) use to adolescents with chronic HBV
The study met its primary endpoint of percentage of patients with HBV DNA levels less than 20 IU/mL at 24 weeks of therapy.
News
FDA rejects bulevirtide for hepatitis D
The FDA cited concerns over the production and delivery of bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor...
From the Journals
Hep C, HIV coinfection tied to higher MI risk with age
“Clinicians providing health care to people with HIV should know their patients’ HCV status and provide support regarding HCV treatment and ways...
News
Few hepatitis C patients receive timely treatment: CDC
More people need to connect to treatments and disparities of access must be reduced.
From the Journals
HCV reinfection uncommon among people who inject drugs
In a new study, most reinfections occurred within 24 weeks of completing treatment.
From the Journals
Liver cancer risk persists after direct-acting antiviral treatment for HCV
“Even with that decline in risk up to 7 years after eradication of hepatitis C with direct-acting antivirals, the risk is still high enough to...
Latest News
Link between pediatric hepatitis and adenovirus 41 still unclear
Although there is a high adenovirus positivity rate amongst these cases, there is not enough evidence yet to say adenovirus 41 is a new cause of...
From the Journals
High residual liver cancer risk in HCV-cured cirrhosis
The predicted probability of HCC in cirrhosis patients was 410 times greater than the general population.